Press Releases Check out the latest news from Tavanta October 28, 2022 Tavanta Therapeutics to Present Preclinical Data for TAVT-135 at the North American Cystic Fibrosis Conference August 01, 2022 Tavanta Therapeutics Announces Completion of Enrollment in Pivotal Phase 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer July 12, 2021 Tavanta Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams May 25, 2021 Tavanta Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of TAVT-45 (abiraterone acetate) Granules for Oral Suspension, a Novel Formulation of Abiraterone Acetate, for the Treatment of Metastatic Prostate Cancer August 31, 2020 Tavanta Therapeutics, a New Specialty Pharmaceutical Company, Has Diverse Pipeline of Novel Drugs and Risk-balanced Approach to Product Development October 29, 2019 DRGT Announces First Subject Dosed in a Phase I Clinical Trial of DRGT-45, a Novel Formulation of Abiraterone Acetate for Prostate Cancer October 21, 2019 Druggability Technologies Holdings, Ltd (DRGT) Announces Appointment of a New Chief Executive Officer and New President of DRGT Research September 18, 2019 DRGT Announces the U.S. FDA IND Application Approval and First Dosing of a Clinical Trial to Evaluate the Bioavailability and Food Effect of Immediate-Release Formulation of Tadalafil (DRGT-99) 123>>
